Testosterone Therapy in diabetic and non-diabetic patients with Chronic Kidney Disease: growing interest and potentially new therapeutic implications

From Top Italian Scientists Journal
Published
January 6, 2026
Title
Testosterone Therapy in diabetic and non-diabetic patients with Chronic Kidney Disease: growing interest and potentially new therapeutic implications
Authors
Sandro La Vignera, Antonio Granata, Rosita A. Condorelli, Livia Basile
DOI
10.62684/CDPX9103
Downloads
Download PDF
Download PDF

Sandro La Vignera(a), Antonio Granata(b), Rosita A. Condorelli(a), Livia Basile(a)

(a) Unità Operativa Endocrinologia Azienda Ospedaliero Universitaria Policlinico “G. Rodolico-S-Marco” – Catania; Università degli Studi di Catania.

(b) Unità Operativa Nefrologia e Dialisi Azienda Ospedaliera per l'Emergenza "Cannizzaro" di Catania.


Correspondence to: sandrolavignera@unict.it

Abstract

This is a short editorial summarizing a highly relevant clinical problem from an epidemiological perspective i.e. the possible pathophysiological links between testosterone deficiency (hypogonadism) in males, a condition known as hypogonadism, and renal function in patients with chronic kidney disease. While these two conditions may share important pathophysiological links, in clinical practice they are mostly considered unrelated. Testosterone hormone replacement therapy (HT) may likely help reduce the progression of chronic kidney disease, although patient phenotyping and the recognition of potential diagnostic biases must be considered to avoid risks.

Declarations

Conflict of Interest

The authors declare no conflict of interest.

References

  1. Zitzmann M (2024) Testosterone deficiency and chronic kidney disease. J Clin Transl Endocrinol 37: 100365. https://doi.org/10.1016/j.jcte.2024.100365.
  2. Zitzmann M (2025) Testosteron – „Benzin“ für den alten Mann? [Testosterone-“Fuel” for old men?]. Inn Med Heidelb 66(1):114-123. https://doi.org/10.1007/s00108-024-01824-x.
  3. Fallara G, Pozzi E, Corsini C, Belladelli F, Boeri L, Capogrosso P, Montorsi F, Salonia A (2022) Morbidity and mortality in men: Role of androgens. Best Pract Res Clin Endocrinol Metab 36(4):101662. https://doi.org/10.1016/j.beem.2022.101662.
  4. Swamy S, Noor SM, Mathew RO (2023) Cardiovascular Disease in Diabetes and Chronic Kidney Disease. J Clin Med 8;12(22):6984. https://doi.org/10.3390/jcm12226984.
  5. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165(5):687-701. https://doi.org/10.1530/EJE-11-0447.
  6. Dandona P, Dhindsa S (2011) Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 96(9):2643-51. https://doi.org/10.1210/jc.2010-2724.
  7. Bikbov B et al (2017) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 395;10225: 709 - 733. https://doi.org/10.1016/S0140-6736(20)30045-3.
  8. Boima V, Agyekum AB, Ganatra K, Agyekum F, Kwakyi E, Inusah J, Ametefe EN, Adu D (2025) Advances in kidney disease: pathogenesis and therapeutic targets. Front Med 12. https://doi.org/ 10.3389 fmed.2025.1526090.
  9. Skiba R, Matyjek A, Syryło T, Niemczyk S, Rymarz A (2020) Advanced Chronic Kidney Disease is a Strong Predictor of Hypogonadism and is Associated with Decreased Lean Tissue Mass. Int J Nephrol Renovasc Dis 5;13:319-327. https://doi.org/10.2147/IJNRD.S275554.
  10. Pan J, Zheng Z, Mao X, Hu D, Wang W, Liao G, Hao Z (2024) Is There a Two-Way Risk between Decreased Testosterone Levels and the Progression and Prognosis of Chronic Kidney Disease? A Cohort Study Based on the National Health and Nutrition Examination Survey Database. World J Mens Health 42(2):429-440. https://doi.org/10.5534/wjmh.230110.
  11. Albaaj F, Sivalingham M, Haynes P, McKinnon G, Foley RN, Waldek S, O'Donoghue DJ, Kalra PA (2006) Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 82;972:693–696. https://doi.org/10.1136/pgmj.2006.045963.
  12. Amiri M, Fahimeh RT, Rahmati M, Soudmand SA, Behboudi-Gandevani S, Sabet Z, Azizi F (2020) Low serum testosterone levels and the incidence of chronic kidney disease among male adults: A prospective population-based study. Andrology 8:575–582. https://doi.org/10.1111/andr.12728.
  13. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M, Carrero JJ (2011) Endogenous Testosterone, Endothelial Dysfunction, and Cardiovascular Events in Men with Nondialysis Chronic Kidney Disease. CJASN 6(7):1617-1625. https://doi.org/10.2215/CJN.10681210.
  14. Iorember FM (2018) Malnutrition in Chronic Kidney Disease. Front Pediatr 6:161. https://doi.org/doi: 10.3389/fped.2018.00161.
  15. Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The Role of Inflammation in CKD. Cells 12(12):1581. https://doi.org/10.3390/cells12121581.
  16. Portolés J, Martín L, Broseta JJ, Cases A (2021) Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med 8. https://doi.org/10.3389/fmed.2021.642296.
  17. Romejko K, Rymarz A, Sadownik H, Niemczyk S (2022) Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease. Nutrients 14(16):3438. https://doi.org/10.3389/fmed.2021.64229610.3390/nu14163438.
  18. Marassi M, Fadini GP (2023) The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol 22, 195. https://doi.org/10.1186/s12933-023-01937-x
  19. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, et al., for the TRAVERSE Study Investigators (2023) Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 389:107-117. https://doi.org/10.1056/NEJMoa2215025.
  20. Alwani M, Al-Zoubi RM, Al-Qudimat A, Yassin A, Aboumarzouk O, Al-Rumaihi K, Talib R, Al-Ansari A (2021) The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. Ann Med Surg (Lond) 69:102748. https://doi.org/10.1016/j.amsu.2021.102748.
  21. Pencina KM, Travison TG, Artz AS, Lincoff AM, Nissen SE, Flevaris P, et al. Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial. JAMA Netw Open 2023;6(10).
  22. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M (2016) Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 39(9):967-81. https://doi.org/10.1007/s40618-016-0480-2. Epub 2016 May 30. PMID: 27241317.
  23. Magnussen LV, Glintborg D, Hermann P, Hougaard DM, Højlund K, Andersen M (2016) Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. Diabetes Obes Metab 18(10):980-9. https://doi.org/10.1111/dom.12701.
  24. Corona G, Maggi M (2022) The role of testosterone in male sexual function. Rev Endocr Metab Disord 23(6):1159-1172. https://doi.org/10.1007/s11154-022-09748-3.
  25. Zhang W, Cui Z, Shen D, Gao L, Li Q (2025) Testosterone levels positively linked to muscle mass but not strength in adult males aged 20-59 years: a cross-sectional study. Front Physiol 16:1512268. https://doi.org/0.3389/fphys.2025.1512268.
  26. Bonnet F, Vaduva P, Halimi JM, Dosda A, Ducluzeau P-H, Koppe L and Fauchier L (2025) Testosterone therapy is associated with reduced risk of acute kidney injury, kidney failure with renal replacement therapy, and cardiovascular events in men with diabetes and hypogonadism. Cardiovascul Diabetol 24:378. https://doi.org/10.1186/s12933-025-02930-2.
  27. Komukai K, Mochizuki S, Yoshimura M (2010) Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol 24(6):687–98. https://doi.org/10.1111 j.1472-8206.2010.00854.x.
  28. Goncharov N, Katsya G, Gaivoronskaya L, Zoloedov V, Uskov V, Gooren L (2012) Effects of short-term testosterone administration on variables of the metabolic syndrome, in particular aldosterone. Horm Mol Biol Clin Investig 12(2):401–6. https://doi.org/10.1515/hmbci-2012-0023.
  29. Yeap BB, Marriott RJ, Dwivedi G, Adams RJ, Antonio L, Ballantyne CM, Bauer DC, Bhasin S, Biggs ML, Cawthon PM, Couper DJ, Dobs AS, Flicker L, Handelsman DJ, Hankey GJ, Hannemann A, Haring R, Hsu B, Martin SA, Matsumoto AM, Mellström D, Ohlsson C, O'Neill TW, Orwoll ES, Quartagno M, Shores MM, Steveling A, Tivesten Å, Travison TG, Vanderschueren D, Wittert GA, Wu FCW, Murray K (2024) Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men: Individual Participant Data Meta-analyses. Ann Intern Med 177(6):768-781. https://doi.org/10.7326/M23-2781.
  30. Li Li, Huixiang Ju, Hao Jin, Hongmei Chen, Mingzhong Sun, Zhongwei Zhou (2022) Low Testosterone Level and Risk of Adverse Clinical Events among Male Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Cohort Studies. J of Healthc Eng. 2022. https://doi.org/10.1155/2022/3630429.
  31. Yassin A, Almehmadi Y, Alwani M, Mahdi M, Jaber A, et al. 2020 Long-term Testosterone Therapy Improves Renal Function in Men with Hypogonadism: A Reallife Prospective Controlled Registry. J Clin Nephrol Res 7(1): 1095. https://doi.org/10.47739/2379-0652/1095.
  32. Gagliano-Jucá T, Basaria S (2019) Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol 16, 555–574. https://doi.org/10.1038/s41569-019-021.
  33. Greenberg DR, Kohn TP, Asanad K, Brannigan RE, Halpern JA (2024) Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. JSM 21(12):1201–1203. https://doi.org/10.1093/jsxmed/qdae138.
Retrieved from ‘https://journal.topitalianscientists.org/index.php?title=Testosterone_Therapy_in_diabetic_and_non-diabetic_patients_with_Chronic_Kidney_Disease&oldid=2467’